Abstract
The sequence of tumorigenesis in the thyroid is unclear. It has been proposed that anaplastic carcinomas of the thyroid develop by dedifferentiation in pre-existing differentiated carcinomas. We reviewed all anaplastic and insular (poorly differentiated) thyroid carcinomas in a consultation practice of thyroid pathology that included more than 400 thyroid cancers. Sixteen tumors (4%) were classified as anaplastic or insular (poorly differentiated) thyroid carcinomas. We examined these cases to determine whether these carcinomas were associated with well-differentiated neoplasms of follicular cell derivation. Ten patients were women and 6 were men, and ages ranged from 29 to 85 years; 10 patients with anaplastic carcinomas and 2 with insular carcinomas were 56 years or older, whereas 3 of the 6 patients with insular carcinomas were 31 years or younger. Four tumors were composed exclusively of anaplastic carcinoma; all were represented only by incisional biopsies. One insular carcinoma infiltrated and destroyed all underlying thyroid tissue. In the remaining total, subtotal, or hemithyroidectomy specimens, areas of well-differentiated papillary or follicular carcinoma were found. Some differentiated papillary lesions had a wide spectrum of morphologies, including Hurthle cell, tall cell, and columnar cell features. In the literature, simultaneous or previous occurrence of well-differentiated thyroid carcinomas with anaplastic carcinomas is extremely variable, ranging from 7–89% of cases. in experimental animals, serial transplantation of differentiated thyroid tumors has been shown to lead to anaplastic transformation. Our findings suggest that the majority of anaplastic thyroid carcinomas in humans arise from well-differentiated tumors. However, only a very small number of differentiated carcinomas progress to anaplastic lesions; the factors underlying this phenomenon remain to be identified.
Similar content being viewed by others
References
Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr. Anaplastic carcinoma of the thyroid. A review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41:2267–2275, 1978.
Bondeson L, Bondeson AG, Ljungberg O, Tibblin S. Oxyphil tumors of the thyroid. Ann Surg 194:677–680, 1981.
Bronner MP, LiVolsi VA. Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer. Mod Pathol 4:637–643, 1991.
Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135–158, 1985.
Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma.” Am J Surg Pathol 8:655–668, 1984.
Fagin JA. Genetic basis of endocrine disease 3. Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 75: 1398–1400, 1992.
Fisher ER, Gregorio R, Shoemaker R, Howat B, Hubay C. The derivation of socalled “giant and spindle cell” undifferentiated thyroid neoplasms. Am J Clin Pathol 61:680–689, 1974.
Frauman AG, Moses AC. Oncogenes and growth factors in thyroid carcinogenesis. Endocrinol Metab Clin North Am 19:479–493, 1990.
Har-El G, Hadar T, Segal K, Levy R, Sidi J. Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer 57:1613–1617, 1986.
Heldin N-E, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin C-H, Westermark B. Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci USA 85:9302–9306, 1993.
Kapp DS, LiVolsi VA, Sanders MM. Anaplastic carcinoma following well-differentiated thyroid cancer: etiological considerations. Yale J Biol Med 5:521–528, 1982.
Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 10:246–255, 1986.
LiVolsi V. Surgical pathology of the thyroid. Philadelphia: W.B. Saunders, 1990.
Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, Giordano G. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68:621–626, 1989.
Moore JH Jr, Bacharach B, Choi HY. Anaplastic transformation of metastatic follicular carcinoma of the thyroid. J Surg Oncol 29:216–221, 1985.
Murray D. The thyroid gland. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Boston: Blackwell Scientific Publications, 1991:293–374.
Orvoine RH, Cantin M, Garzon S, Billick RC, Stephens H, Strykowski H. Dedifferentiation of a transplantable papillary thyroid carcinoma over a 15-year period. Cancer 52:1720–1727, 1983.
Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855, 1983.
Samaan NA, Ordoñez NG. Uncommon types of thyroid cancer. Endocrinol Metab Clin North Am 19:637–648, 1990.
Spires JR, Schwartz MR, Miller RH. Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 114:40–44, 1988.
Ueda G, Furth J. Sarcomatoid transformation of transplanted thyroid carcinoma: similarity to anaplastic human thyroid carcinomas. Arch Pathol Lab Med 83:3–12, 1967.
Vogelstem B, Fearon ER, Hamilton SR, Kern SE, Prcisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 319: 525–532, 1988.
Williams DW, Williams ED, Wynford-Thomas D. Evidence for autocrine production of IGF-1 in human thyroid adenomas. Mol Cell Endocrinol 61:139–143, 1989.
Yoshida A, Kamma H, Asaga T, Masuzawa C, Kawahara S, Mimura T, Ito K. Proliferative activity in thyroid tumors. Cancer 69:2548–2552, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van der Laan, B.F.A.M., Freeman, J.L., Tsanq, R.W. et al. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocr Pathol 4, 215–221 (1993). https://doi.org/10.1007/BF02915464
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02915464